CervoMed
CRVO----
CervoMed (CRVO)
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
CervoMed Analyst Rating
View MoreForecast & Rating
Jul 15, 2026Price forecast
$19.50633.08%
Forecast & RatingStrong buy
7analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 14 at 06:35 AM
CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trial
- Unusual Whales · Jul 14 at 06:31 AM
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
- PUBT · Jul 9 at 06:34 AM
CervoMed completes enrollment in Phase 2a neflamapimod trial for nonfluent PPA
- PUBT · Jul 6 at 06:33 AM
CervoMed to present new neflamapimod Phase 2 data in Lewy body dementia at AAIC 2026
- StockTitan · Jul 5 at 10:30 PM
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 | CRVO Stock News
- Tip Ranks · Jun 25 at 07:56 AM
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
